TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03586544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol Sulfate
Description: Participants will inhale 2 puffs of albuterol (90mcg per actuation). After 15 minutes, participants will undergo an exercise induced bronchoconstriction test

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol Sulfate
Description: Participants will inhale 2 puffs of albuterol (90mcg per actuation). After 15 minutes, participants will undergo an exercise induced bronchoconstriction test

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interval Warm-up exercise
Description: Participants will undergo eight 30 sec bouts of high intensity exercise with 45 second recovery between bouts. After 15 minutes, participants will undergo an exercise induced bronchoconstriction test

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interval Warm-up exercise
Description: Participants will undergo eight 30 sec bouts of high intensity exercise with 45 second recovery between bouts. After 15 minutes, participants will undergo an exercise induced bronchoconstriction test
Study: NCT01888406

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Self-Help

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Pure Self-Help
Study: NCT02466295

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Volume-controlled ventilation
Description: I-gel will be inserted into the patient's mouth. After confirmation of adequate ventilation with the i-gel, the patient's lungs will be mechanically ventilated using the volume-controlled mode with tidal volume 8 ml/kg during surgery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pressure-controlled ventilation
Description: I-gel will be inserted into the patient's mouth. After confirmation of adequate ventilation with the i-gel, the patient's lungs will be mechanically ventilated using the pressure-controlled mode with tidal volume 8 ml/kg during surgery.
Study: NCT01512966

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VEGF Trap-Eye (BAY86-5321)
Description: Subjects in the VEGF Trap-Eye group will receive intravitreal injections every 8 weeks following a loading phase with injections given every 4 weeks. The overall treatment period is 48 weeks.
Study: NCT04008420

Intervention type: OTHER
Intervention: monitoring of the oxygen reserve index
Description: The investigators will enroll adult patients who will undergo robotic esophagectomy under general anesthesia. The oxygen reserve index will be monitored continuously during anesthesia. The postoperative complications will be recorded after surgery.
Study: NCT04156750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Administered orally.

Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Description: Administered orally.
Study: NCT02529761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib will be supplied as 200 mg tablets. All subjects will take two tablets of sorafenib (200 mg tablets) twice daily (each morning and evening).
Study: NCT00554801

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Audiological testing
Description: Subjects will take part in a battery of audiological tests meant to evaluate the function and status of the auditory system. These tests are similar to the kinds of testing carried out routinely in audiology clinics, and include behavioral tests of pure tone hearing, speech perception, and central auditory function, and electrophysiological testing of the middle ear and of the central auditory system.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Audiological testing
Description: Subjects will take part in a battery of audiological tests meant to evaluate the function and status of the auditory system. These tests are similar to the kinds of testing carried out routinely in audiology clinics, and include behavioral tests of pure tone hearing, speech perception, and central auditory function, and electrophysiological testing of the middle ear and of the central auditory system.
Study: NCT00296426

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: New technology - PAML
Study: NCT01712594

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Closed Loop Procedure (Medtronic)
Description: The procedure A is the device running under normal conditions, procedure B will incorporate an induced calibration error.
Study: NCT02241694

Intervention type: OTHER
Intervention: No treatment given
Description: No treatment given. Participants are to complete a questionnaire in the study.
Study: NCT04539951

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline 200 milligram(mg)
Description: All included participants will receive sertraline, initially at 50mg/d, with a weekly 50mg/d further increase, to the maximum recommended dosage (200mg/d) or to the maximum tolerated dosage (less than 200mg/d). Patients will be on their maximum dose by week 4, so allowing an assessment of response at 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline 300 milligram(mg)
Description: In experimental phase II, the patients in this group will remain on sertraline (higher dosage): where sertraline 200mg has been tolerated, dosage will be increased by 50mg fortnightly to a maximal dose of 300mg/d or to the maximum tolerable dose (less than 300mg/d).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluvoxamine
Description: Fluvoxamine will be initiated at a dose of 50mg/d, increasing quickly to a maximal dose of 300mg/d or the maximum tolerated dose by week 4.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine
Description: venlafaxine will be initiated at 75mg/d, increasingly weekly by 75mg/day, to a maximal dose of 300 mg/d or the maximum tolerated dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Augment with Memantine
Description: Sertraline will be augmented with memantine initially at 5mg/d, and increasing by 5mg/d weekly to a maximal dose of 20mg/d (10mg twice daily) or the maximum tolerated dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Augment with Aripiprazole
Description: Sertraline will be augmented with aripiprazole, initially at 5mg/d, and increasing by 5mg/d weekly to a maximal dose of 20mg/d or the maximum tolerated dose
Study: NCT02814825

Intervention type: OTHER
Intervention: ViviGen
Description: ViviGen Cellular Bone Matrix is a formulation of cryopreserved viable cortical cancellous bone matrix and demineralized bone. ViviGen is a Human Cells, Tissues, and Cellular and Tissue-based Product (HCT/P) as defined by the U.S. Food and Drug Administration in 21 CFR 127 1.3(d).
Study: NCT01890889

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ad-Chol-Pre

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Half-dose Ad-Chol-Pre

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Defatted egg yolk without the active ingredient of the other two interventions
Study: NCT02529761

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: The first treatment of TACE should be completed within 3-7 days after the administration of sorafenib started. In all cases, TACE consists of an injection containing a mixture of chemotherapeutic agents and lipiodol followed by embolization with polyvinyl alcohol (PVA) particles until complete stasis was achieved in the tumor-feeding vessels.Tumor-feeding vessels should be selected/superselected whenever possible. TACE will be repeated on demand depending on the radiological response.
Study: NCT02206841

Intervention type: PROCEDURE
Intervention: Liver biopsy
Description: Percutaneously liver biopsy will be performed for evaluate steatosis and fibrosis.

Intervention type: DEVICE
Intervention: ARFI
Description: Acoustic radiation force impulse (ARFI) imaging will be performed for evaluate fibrosis of liver.

Intervention type: DEVICE
Intervention: SWE
Description: Supersonic shear wave elastography (SWE) will be performed for evaluate fibrosis of liver.

Intervention type: DEVICE
Intervention: Transient elastography
Description: Transient elastography will be performed for evaluate fibrosis of liver.
Study: NCT01883791

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SBIRT
Description: See above Arm description.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Health Education
Description: See Arm Description.
Study: NCT04386109

Intervention type: OTHER
Intervention: No intervention - exposure is to COVID-19
Description: No intervention - exposure is to COVID-19

Intervention type: OTHER
Intervention: No intervention - exposure is to COVID-19
Description: No intervention - exposure is to COVID-19
Study: NCT05659329

Intervention type: DEVICE
Intervention: Simplex HV
Description: Simplex HV bone cement is a fast-setting acrylic resin for use in bone surgery. Mixing the two separate sterile components produces a ductile bone cement which, after hardening, fixes the implant and transfers stresses produced during movement evenly to the bone.

Intervention type: DEVICE
Intervention: Simplex HV
Description: Simplex HV bone cement is a fast-setting acrylic resin for use in bone surgery. Mixing the two separate sterile components produces a ductile bone cement which, after hardening, fixes the implant and transfers stresses produced during movement evenly to the bone.
Study: NCT03966950

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: melatonin
Description: melatonin 10 mg per os in the preoperative night and the immediate postoperative night and the first and second postoperative nights.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: placebo taken per os in the preoperative night and the immediate postoperative night and the first and second postoperative nights
Study: NCT04372784

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: Cryotherapy entails introducing a 9 French catheter via the endoscope's accessory port. The catheter is advanced until it is visualized on the endoscopy monitor. Under 4 psi pressure, liquid nitrogen is sprayed from the catheter for twenty seconds over each four-centimeter segment of stricture

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Esophagogastroduodenoscopy with Balloon Dilatation
Description: This procedure entails deploying a balloon via the accessory port of the esophagogastroduodenoscope under direct visualization and serially inflating the balloon. Balloon dilatation disrupts not only the muscular rings surrounding strictures but also the granulation tissue composing the strictures.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophagogastroduodenoscopy with Balloon Dilatation
Description: This procedure entails deploying a balloon via the accessory port of the esophagogastroduodenoscope under direct visualization and serially inflating the balloon. Balloon dilatation disrupts not only the muscular rings surrounding strictures but also the granulation tissue composing the strictures.
Study: NCT03314363

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: blood gas analysis under citrate predilution
Description: blood gas analysis of blood on different sample points and dialysis fluid

Intervention type: DEVICE
Group type: OTHER
Intervention: filter replacement
Description: Using local protocol: stop and disconnect CRRT, replace filter and reconnect and restart CRRT.

Intervention type: DEVICE
Group type: OTHER
Intervention: IC
Description: monitor patients during the whole study period with indirect calorimetry

Intervention type: DRUG
Group type: OTHER
Intervention: NaCl predilution
Description: Replace citrate predilution with NaCl
Study: NCT02529761

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: The first treatment of TACE should be completed within 3-7 days after the administration of sorafenib started. In all cases, TACE consists of an injection containing a mixture of chemotherapeutic agents and lipiodol followed by embolization with polyvinyl alcohol (PVA) particles until complete stasis was achieved in the tumor-feeding vessels.Tumor-feeding vessels should be selected/superselected whenever possible. TACE will be repeated on demand depending on the radiological response.
Study: NCT01695057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01068041

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PH3
Description: Each PH3 tablet, 530 mg/tablet, contains 250 mg of active ingredient. The placebo tablet contains no active ingredient.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PH3
Description: Each PH3 tablet, 530 mg/tablet, contains 250 mg of active ingredient. The placebo tablet contains no active ingredient.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PH3
Description: Each PH3 tablet, 530 mg/tablet, contains 250 mg of active ingredient. The placebo tablet contains no active ingredient.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PH3
Description: Each PH3 tablet, 530 mg/tablet, contains 250 mg of active ingredient. The placebo tablet contains no active ingredient.
Study: NCT04585399

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency management
Description: Financial incentives for attending bup appointments and demonstrating opioid abstinence. Rides will also be provided for up to two clinic visits per week.
Study: NCT02387749

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cells
Description: collection of stem cells by bone marrow biopsy from iliac crest, then culture for 1 month , then IV transfusion on 2 sessions to the same patient
Study: NCT02371135

Intervention type: GENETIC
Intervention: colonic biopsies
Study: NCT03850067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90011
Description: CC-90011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin
Study: NCT02371135

Intervention type: GENETIC
Intervention: questionnaires
Study: NCT02787967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 1535 35/4µg NEXThaler®
Description: 4 (four) inhalations (total dose: BDP/FF 140/16 µg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: free comb. beclomethasone DPI and formoterol DPI
Description: 2 (two) inhalations BDP 100 µg DPI + 4 (four) inhalations FF 6 µg DPI (total dose: BDP 200 µg + FF 24 µg
Study: NCT02357784

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurometer
Description: The purpose of Current Perception Threshold (CPT) testing is to help physicians better understand how Sacral Neuromodulation affects the nerves of patients with dual incontinence. CPT Testing involves the use of a portable battery-operated machine which will stimulate the subject's nerves via an electrical stimulation. Electrodes will be placed via a catheter in to the subject's urethra and rectum, and the electrical current will be increased gradually until the subject feels the onset of tingling, buzzing, or warmth at the site of the electrode. The electrical current will then gradually decrease until no sensation of stimulation is felt. The procedure will then be repeated where the subject will be asked to hold the test button to increase the stimulus intensity above their sensory threshold (above the point where they can feel it) until the device automatically shuts off.
Study: NCT00633438

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched oral capsule administered 1 hour prior to surgery and matched oral capsule administered post surgery as needed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 400 mg oral capsule as single dose administered 1 hour prior to surgery and 200 mg oral capsule as single dose administered post surgery as needed
Study: NCT00032019

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Cycle 1: 300 ug (BW \< = 70 kg) or 480ug (BW \>70 kg) sub Q injection Day 6 until ANC \> 5000/uL after nadir counts Subsequent cycle dosages based on previous cycle toxicity or Day 1 Tx toxicity

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375 mg/sq m IV infusion Day 1 Cycle 1 Subsequent cycle dosage based on previous cycle or day 1 of tx toxicities

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 750 mg/sq m IV infusion on Day 5 Cycle 1 Subsequent cycle dosage based on previous cycle or day 1 treatment toxicities

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: 10 mg/sq m/day continuous IV infusion on Days 1-4 Cycle 1 Subsequent cycle dosages based on previous cycle and Day 1 treatment toxicities

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: 50 mg/sq m/day continuous IV infusion Days 1-4 Cycle 1 Subsequent cycle dosages based on previous cycle and day 1 of treatment toxicities

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 60 mg/sq m PO bid days 1-5 of ea cycle
Study: NCT02882646

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bi-ADLER
Description: Subjects will be asked to use the Bi-ADLER for 60 minutes. All subjects will be seated on the Bi-ADLER and asked to perform a battery of bimanual evaluation tasks (creating ovals, standard ADL tasks like pouring, reaching, drinking etc).
Study: NCT02156635

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Study: NCT00032019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: 0.4 mg/sq m/day continuous IV infusion uncapped on Days 1-4 Cycle 1 Subsequent cycle dosages based on previous cycle and day 1 of treatment toxicities
Study: NCT01259752

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: compression stockings
Description: compression stockings
Study: NCT02156635

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Constraint-Induced Movement Therapy

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Constraint-Induced Movement Therapy
Study: NCT01259752

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: standard non compressive stockings
Description: standard non compressive stockings
Study: NCT02709434

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducational programme
Description: Activity diary analysis and a structured programme of intervention

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard care
Description: Usual IBD management

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Usual IBD management
Study: NCT02306187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edirol
Description: Edirol 0.5 or 0.75ug once every day oral treatment for at least 1 year after initial visit.
Study: NCT02156635

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo
Study: NCT02631499

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: TACE is performed 4-6 weeks after hepatectomy. Epirubicin and lipiodol are used in TACE.
Study: NCT01839188

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PR5I
Description: Hexavalent PR5I vaccine (DTaP-HB-IPV-Hib = Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed \[DTaP\], Hepatitis B \[HB; Recombinant DNA\], Inactivated Poliovirus \[IPV\], and Haemophilus influenzae type b \[Hib\] conjugate vaccine \[adsorbed\]) at 0.5 mL for IM injection (left upper thigh) at 2 and 6 months of age.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pediacel®
Description: Pentavalent Pediacel® vaccine (DTaP-IPV-Hib = Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed \[DTaP\], Inactivated Poliovirus \[IPV\], and Haemophilus influenzae type b \[Hib\] conjugate vaccine \[adsorbed\]) at 0.5 mL for IM injection (left upper thigh) at 4 months of age.
Study: NCT02631499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Epirubicin is a chemotherapy drug used in TACE

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lipiodol
Description: lipiodol is a kind of embolization material used in TACE
Study: NCT01839188

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NeisVac-C®
Description: Meningococcal group C (MCC) polysaccharide conjugate vaccine (adsorbed) at 0.5 mL for IM injection (right upper thigh) at 2 and 4 months of age.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RotaTeq®
Description: Human-bovine rotavirus reassortants (live) vaccine 2 mL oral administration at 2, 4 and 6 months of age. RotaTeq® administered prior to any other vaccine administration to avoid having the infant participants spit up the RotaTeq® when crying.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevenar 13®
Description: Pneumococcal polysaccharide conjugate vaccine \[PCV; 13-valent, adsorbed\]) at 0.5 mL for IM injection (right upper thigh) at 2 and 4 months of age.
Study: NCT03314363

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: blood gas analysis under NaCl predilution
Description: repeat blood gas analysis of blood on different sample points and dialysis fluid
Study: NCT03355287

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Traditionally Threshed Teff (TTT)
Description: The intervention will take place for 7 months in Debre Zeit where the the arm will be fed injera based on teff that are threshed traditionally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lab Threshed Teff (LTT)
Description: The intervention will take place for 7 months in Debre Zeit where this arm will be fed injera from teff that is threshed using a modern thresher.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fortified Lab Threshed Teff (FTT)
Description: The intervention will take place for 7 months in Debre Zeit where this arm will be fed injera from teff that is threshed using a modern thresher. In addition, they will receive Ferrous sulfate drops
Study: NCT03167580

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: restricted PEEP
Description: Patients are randomized and ventilated with restricted PEEP (the lowest possible PEEP level, 0 - 5 cm H2O)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: liberal PEEP
Description: Patients are randomized and ventilated with liberal PEEP (the median PEEP level used in the Netherlands, 8 cm H2O)
Study: NCT03870711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine spray
Description: 10% lidocaine spray 4 puffs

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile water 4 puffs